IRIS
QUARTUCCIO, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.986
AS - Asia 8.630
EU - Europa 5.153
SA - Sud America 1.633
Continente sconosciuto - Info sul continente non disponibili 1.031
AF - Africa 226
OC - Oceania 11
AN - Antartide 1
Totale 35.671
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.455
SG - Singapore 3.966
CN - Cina 1.709
BR - Brasile 1.272
UA - Ucraina 1.065
IT - Italia 1.053
HK - Hong Kong 869
VN - Vietnam 778
DE - Germania 696
FI - Finlandia 416
RU - Federazione Russa 402
FR - Francia 362
GB - Regno Unito 302
CA - Canada 249
BD - Bangladesh 247
IE - Irlanda 244
SE - Svezia 225
IN - India 209
TR - Turchia 195
AR - Argentina 123
KR - Corea 112
EC - Ecuador 72
JP - Giappone 72
ID - Indonesia 68
AT - Austria 66
IQ - Iraq 66
MX - Messico 64
ZA - Sudafrica 64
NL - Olanda 61
CO - Colombia 55
PL - Polonia 47
ES - Italia 39
PK - Pakistan 39
IL - Israele 38
JM - Giamaica 32
CZ - Repubblica Ceca 29
EG - Egitto 29
UZ - Uzbekistan 29
IR - Iran 28
PH - Filippine 28
VE - Venezuela 28
TT - Trinidad e Tobago 27
SA - Arabia Saudita 26
BE - Belgio 25
CR - Costa Rica 25
MA - Marocco 25
CL - Cile 24
LT - Lituania 23
PY - Paraguay 23
SC - Seychelles 23
TG - Togo 20
GT - Guatemala 19
HN - Honduras 19
NI - Nicaragua 19
TN - Tunisia 18
AE - Emirati Arabi Uniti 17
EE - Estonia 16
MY - Malesia 16
CW - ???statistics.table.value.countryCode.CW??? 15
SV - El Salvador 15
PT - Portogallo 13
UY - Uruguay 13
AZ - Azerbaigian 12
DO - Repubblica Dominicana 12
GP - Guadalupe 12
PE - Perù 12
GR - Grecia 11
JO - Giordania 11
KE - Kenya 11
KZ - Kazakistan 11
NP - Nepal 11
OM - Oman 11
PR - Porto Rico 11
AL - Albania 10
BO - Bolivia 10
DZ - Algeria 10
TH - Thailandia 10
RO - Romania 9
BB - Barbados 7
LB - Libano 7
TW - Taiwan 7
BS - Bahamas 6
EU - Europa 6
KG - Kirghizistan 6
LK - Sri Lanka 6
AU - Australia 5
BY - Bielorussia 5
HR - Croazia 5
NZ - Nuova Zelanda 5
PA - Panama 5
CH - Svizzera 4
ET - Etiopia 4
NO - Norvegia 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BH - Bahrain 3
BN - Brunei Darussalam 3
GA - Gabon 3
KW - Kuwait 3
PS - Palestinian Territory 3
Totale 34.603
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.634
Singapore 1.596
Ashburn 1.534
Ann Arbor 1.122
Fairfield 1.061
San Jose 1.024
Houston 991
Council Bluffs 908
Beijing 858
Hong Kong 840
Chandler 768
Jacksonville 685
Wilmington 521
Seattle 448
Boardman 420
Dearborn 415
Cambridge 335
Los Angeles 287
Lauterbourg 285
Ho Chi Minh City 242
Dublin 239
Princeton 230
Dallas 210
Santa Clara 194
Udine 181
Buffalo 139
Hanoi 139
Izmir 139
São Paulo 139
New York 134
Hefei 129
Helsinki 107
Seoul 105
North Bergen 102
Milan 101
Redondo Beach 98
Des Moines 89
San Diego 86
Phoenix 85
Dong Ket 80
Munich 79
Nuremberg 74
The Dalles 71
Frankfurt am Main 64
Orem 62
Ogden 60
Chicago 57
Montreal 57
Atlanta 53
Rome 53
Norwalk 52
Brooklyn 51
Tokyo 48
Toronto 46
Ottawa 45
London 44
Warsaw 43
Redmond 42
Denver 40
Rio de Janeiro 39
Nanjing 38
Trieste 38
Johannesburg 37
Mumbai 35
Amsterdam 33
Pittsburgh 33
San Francisco 32
Chennai 30
Belo Horizonte 28
Da Nang 28
Stockholm 28
Tashkent 28
Haiphong 27
Belluno 26
San Mateo 26
Lappeenranta 25
Quito 25
Boston 24
Düsseldorf 24
Guangzhou 24
Guayaquil 24
Philadelphia 24
Brasília 23
Curitiba 23
Naples 23
Vienna 23
Bologna 22
Kingston 22
Newark 22
Brno 21
Turin 21
Turku 21
Baghdad 20
Brussels 20
Hải Dương 20
Lomé 20
Manchester 20
Managua 19
Mexico City 19
Salvador 19
Totale 20.795
Salva come PNG Salva come JPEG
Nome #
An overview on advantages and limitations of serological assays for saRs-coV-2 infectious disease 224
Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. 216
Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands 209
A randomized controlled trial of rituximab for treatment of severe cryoglobulinemic vasculitis. 204
A randomized, controlled, multicenter phase iii study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) Ann Rheum Dis 2010;69(Suppl3):93 200
Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies 200
Validation of the classification criteria for cryoglobulinaemic vasculitis. 197
Gitelman syndrome disclosed by calcium pyrophosphate deposition disease: Early diagnosis by ultrasonographic study 196
Pain management in cryoglobulinaemic syndrome 194
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 194
AB0695 Anti-prothrombin/phosphatidyl-serine complex autoantibodies in antiphospholipid syndrome: Preliminary data using a new ELISA method 193
Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus 192
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis 191
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. 187
Pachydermodactyly: The role of ultrasonography and dermoscopy for diagnosis 186
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study 180
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 179
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 178
A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation 176
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 176
Gestione di farmaci biologici ad alto costo in reumatologia e utilizzo di predittori di risposta: il modello dell'anticorpo monoclonale anti-CD20 (Rituximax) nell'artrite reumatoide 175
Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. 174
Efficacy of intravenous cyclosporine in a case of cytophagic histiocytic panniculitis complicated by haemophagocytic syndrome after visceral leishmania infection 174
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 173
Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs 173
Accuracy of Computer-Guided Flapless Implant Surgery in Fully Edentulous Arches and in Edentulous Arches With Fresh Extraction Sockets 172
BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands 171
Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. 170
Use of teriparatide in osteoporosis due to active rheumatic diseases 170
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis 170
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome 169
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. 168
Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. 167
A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) 166
Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection 165
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care 165
Strontium ranelate and femural fracture healing during rheumatoid arthritis and osteoporosis 163
Role e of oral cyclophosphamide in the treatment of giant cell arteritis 162
Treatment of rheumatoid arthritis with rituximab: an update and possible indications. 161
Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients 161
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis 160
Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis 160
Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. 160
Patient-reported impact of spondyloarthritis on work disability and working life: The ATLANTIS survey 159
Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients 159
Ciclosporina e tacrolimus nella miosite da corpi inclusi: efficacia clinica, sicurezza e risparmio nell'uso dei corticosteroidi 158
Mycophenolic Acid AUC estimation in patients with lupus nephritis using an algorithm validated in an heart transplanted population 158
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 158
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. 158
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides. 157
Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution 157
Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease 157
B lymphocyte stimulator (BLyS) and monocytes: possible role in autoimmune diseases with a particular reference to rheumatoid arthritis 156
Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis 156
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis 155
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 155
Sjögren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at the crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both diseases 153
L. Quartuccio, M. Fabris, M. Maset, E. Pontarini, A. Zabotti, S. De Vita Bone marrow b-cell expansion in mixed cryoglobulinemia: association with nephritis and response to rituximab 153
Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al 152
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC) 152
Classification of cryoglobulinemic vasculitis 151
A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. 151
A randomized, controlled, multicenter phase III study of the efficacy and safety of Rituximab (RTX) monotherapy versus thebest available treatment in patients with mixedcryoglobulinemia syndrome, on behalf of the rituximab studygroup in cryoglobulinemic sindrome. 151
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 150
Myositis in primary sjögren's syndrome: data from a multicenter cohort 148
Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study 147
Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis: reply 146
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients 146
The Challenge of IBD-Related Arthritis Screening Questionnaires in Early and Predominantly Entheseal Phenotypes 145
Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. 145
Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement 145
Pregnancy and fetal outcome in patients with an established diagnosis of primary sjögren's syndrome 144
Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. 144
Gastrointestinal Involvement in Systemic Vasculitis 143
Rituximab for rheumatoid arthritis refractory to both conventional therapy and anti-tumor necrosis factor therapy: results of a multi-centre observational italian studyann 142
A clinical-genetic score to identify surgically resected colorectal cancer patients benefiting from an adjuvant fluoropyrimidine-based therapy 141
Variations in lumbar and femural bmd after rituximab therapy in active rheumatoid arthritis 140
Chlamydophila psittaci subclinical infection in chronic polyarthritis 140
Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer 139
The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis 139
Post-covid-19 arthritis and sacroiliitis: Natural history with longitudinal magnetic resonance imaging study in two cases and review of the literature 139
Pleuritis is a red flag for Adult-onset Still's disease which may require biologic therapies. 138
Rituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinaemia 137
efficacy of methotrexate in polymyalgia rheumatica 137
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. 137
Fetal Outcome in Patients with an Established Diagnosis of Primary Sjögren’s Syndrome 136
Preliminary classification criteria for the cryoglobulinaemic vasculitis 136
Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. 136
Safety of Rituximab in different rheumatic autoimmune diseases. A single centre experience in 85 cases. 2008 135
Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus 135
Delayed Positivization of Cerebral Angiography in Reversible Cerebral Vasoconstriction Syndrome (RCVS) Presenting with Recurrent Subarachnoid Haemorrhage. 135
Clinical characterization and treatment outcome in a monocentric cohort of 45 patients with adult onset still's disease 134
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjo¨gren’s Syndrome: Results of the Beliss Study. 134
Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome 134
Rheumatoid factor positivity, a lower disability and a lower number of anti-tnf agents failed are associated with response to rituximab in rheumatoid arthritis 134
Eosinophilic myocarditis: comprehensive update on pathophysiology, diagnosis, prognosis and management 133
Articular and peripheral nervous system involvement are linked to the long-term outcome in primary Sjögren's syndrome: The relevance of single organ manifestations rather than a composite score as predictors 133
Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. 132
Gastrointestinal involvement in systemic vasculitis 132
The role of the il-6 promoter p in predicting rituximab efficacy in rheumatoid artolymorphism 131
Totale 15.969
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.979
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.979
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.216 0 0 0 0 44 48 91 109 25 235 369 295
2022/20232.035 248 95 38 221 208 544 35 147 296 38 77 88
2023/2024763 109 62 29 19 144 89 30 64 99 60 21 37
2024/20255.380 121 403 231 158 236 233 337 358 709 492 771 1.331
2025/202610.730 789 1.026 943 1.044 1.543 919 1.092 391 735 872 837 539
2026/20274.371 423 805 986 1.849 308 0 0 0 0 0 0 0
Totale 35.671